当前可用的COVID-19疫苗的过敏反应:病理生理学、因果关系及治疗考量
Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations.
作者信息
Kounis Nicholas G, Koniari Ioanna, de Gregorio Cesare, Velissaris Dimitris, Petalas Konstantinos, Brinia Aikaterini, Assimakopoulos Stelios F, Gogos Christos, Kouni Sophia N, Kounis George N, Calogiuri GianFranco, Hung Ming-Yow
机构信息
Department of Internal Medicine, Division of Cardiology, University of Patras Medical School, 26221 Patras, Greece.
Department of Internal Medicine, Division of Cardiology, University Hospital of South Manchester NHS Foundation Trust, Manchester M23 9LT, UK.
出版信息
Vaccines (Basel). 2021 Mar 5;9(3):221. doi: 10.3390/vaccines9030221.
Vaccines constitute the most effective medications in public health as they control and prevent the spread of infectious diseases and reduce mortality. Similar to other medications, allergic reactions can occur during vaccination. While most reactions are neither frequent nor serious, anaphylactic reactions are potentially life-threatening allergic reactions that are encountered rarely, but can cause serious complications. The allergic responses caused by vaccines can stem from activation of mast cells via Fcε receptor-1 type I reaction, mediated by the interaction between immunoglobulin E (IgE) antibodies against a particular vaccine, and occur within minutes or up to four hours. The type IV allergic reactions initiate 48 h after vaccination and demonstrate their peak between 72 and 96 h. Non-IgE-mediated mast cell degranulation via activation of the complement system and via activation of the Mas-related G protein-coupled receptor X2 can also induce allergic reactions. Reactions are more often caused by inert substances, called excipients, which are added to vaccines to improve stability and absorption, increase solubility, influence palatability, or create a distinctive appearance, and not by the active vaccine itself. Polyethylene glycol, also known as macrogol, in the currently available Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines, and polysorbate 80, also known as Tween 80, in AstraZeneca and Johnson & Johnson COVID-19 vaccines, are excipients mostly incriminated for allergic reactions. This review will summarize the current state of knowledge of immediate and delayed allergic reactions in the currently available vaccines against COVID-19, together with the general and specific therapeutic considerations. These considerations include: The incidence of allergic reactions and deaths under investigation with the available vaccines, application of vaccination in patients with mast cell disease, patients who developed an allergy during the first dose, vasovagal symptoms masquerading as allergic reactions, the COVID-19 vaccination in pregnancy, deaths associated with COVID-19 vaccination, and questions arising in managing of this current ordeal. Careful vaccine-safety surveillance over time, in conjunction with the elucidation of mechanisms of adverse events across different COVID-19 vaccine platforms, will contribute to the development of a safe vaccine strategy. Allergists' expertise in proper diagnosis and treatment of allergic reactions is vital for the screening of high-risk individuals.
疫苗是公共卫生领域最有效的药物,因为它们能控制和预防传染病的传播并降低死亡率。与其他药物类似,接种疫苗期间可能会发生过敏反应。虽然大多数反应并不常见也不严重,但过敏反应是潜在威胁生命的过敏反应,很少发生,但可能导致严重并发症。疫苗引起的过敏反应可能源于肥大细胞通过Fcε受体-1的激活(I型反应),由针对特定疫苗的免疫球蛋白E(IgE)抗体之间的相互作用介导,反应在数分钟内或长达四小时内发生。IV型过敏反应在接种疫苗后48小时开始,并在72至96小时达到峰值。通过补体系统激活和通过Mas相关G蛋白偶联受体X2激活的非IgE介导的肥大细胞脱颗粒也可诱导过敏反应。反应更多是由添加到疫苗中以提高稳定性和吸收性、增加溶解度、影响适口性或创造独特外观的惰性物质(称为辅料)引起的,而不是由活性疫苗本身引起的。目前可用的辉瑞- BioNTech和莫德纳新冠病毒mRNA疫苗中的聚乙二醇(也称为聚环氧乙烷),以及阿斯利康和强生新冠病毒疫苗中的聚山梨酯80(也称为吐温80),是最常被认为与过敏反应有关的辅料。本综述将总结目前关于现有新冠病毒疫苗中速发型和迟发型过敏反应的知识现状,以及一般和特殊的治疗考虑因素。这些考虑因素包括:现有疫苗正在调查的过敏反应和死亡发生率、肥大细胞疾病患者的疫苗接种应用、在第一剂接种期间出现过敏的患者、伪装成过敏反应的血管迷走神经症状、孕期的新冠病毒疫苗接种、与新冠病毒疫苗接种相关的死亡,以及在应对当前这场严峻考验中出现的问题。随着时间的推移进行仔细的疫苗安全性监测,结合阐明不同新冠病毒疫苗平台上不良事件的机制,将有助于制定安全的疫苗策略。过敏症专科医生在正确诊断和治疗过敏反应方面的专业知识对于筛查高危个体至关重要。